CN114470123A - Medical gynecological gel for treating HPV (human papillomavirus) infection and preparation method thereof - Google Patents
Medical gynecological gel for treating HPV (human papillomavirus) infection and preparation method thereof Download PDFInfo
- Publication number
- CN114470123A CN114470123A CN202210184541.9A CN202210184541A CN114470123A CN 114470123 A CN114470123 A CN 114470123A CN 202210184541 A CN202210184541 A CN 202210184541A CN 114470123 A CN114470123 A CN 114470123A
- Authority
- CN
- China
- Prior art keywords
- parts
- hpv
- gynecological gel
- infection
- medical gynecological
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241000701806 Human papillomavirus Species 0.000 title abstract description 44
- 208000015181 infectious disease Diseases 0.000 title abstract description 3
- 230000009385 viral infection Effects 0.000 claims abstract description 23
- 244000116484 Inula helenium Species 0.000 claims abstract description 14
- 235000002598 Inula helenium Nutrition 0.000 claims abstract description 14
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 14
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 13
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 13
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 13
- 240000005523 Peganum harmala Species 0.000 claims abstract description 13
- 235000005126 Peganum harmala Nutrition 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 13
- 241000759909 Camptotheca Species 0.000 claims abstract description 12
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 12
- 240000001659 Oldenlandia diffusa Species 0.000 claims abstract description 12
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims abstract description 7
- 235000007685 Pleurotus columbinus Nutrition 0.000 claims abstract description 6
- 240000001462 Pleurotus ostreatus Species 0.000 claims abstract description 6
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims abstract description 6
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 5
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 4
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 4
- 208000006374 Uterine Cervicitis Diseases 0.000 claims abstract 2
- 206010046914 Vaginal infection Diseases 0.000 claims abstract 2
- 201000008100 Vaginitis Diseases 0.000 claims abstract 2
- 206010008323 cervicitis Diseases 0.000 claims abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 16
- 208000009608 Papillomavirus Infections Diseases 0.000 claims description 9
- 244000153955 Reynoutria sachalinensis Species 0.000 claims description 9
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 8
- 241000758794 Asarum Species 0.000 claims description 8
- 235000013717 Houttuynia Nutrition 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 8
- 229960001631 carbomer Drugs 0.000 claims description 8
- 239000012153 distilled water Substances 0.000 claims description 8
- 239000003906 humectant Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 7
- 241000124033 Salix Species 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 5
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 4
- 208000003251 Pruritus Diseases 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010037888 Rash pustular Diseases 0.000 claims 1
- 208000027744 congestion Diseases 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 208000029561 pustule Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000003385 bacteriostatic effect Effects 0.000 abstract 1
- 238000011160 research Methods 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 4
- 241000329195 Sparganium erectum Species 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 2
- 241000759905 Camptotheca acuminata Species 0.000 description 2
- 241000195950 Equisetum arvense Species 0.000 description 2
- 239000005768 Equisetum arvense L. Substances 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 241000475481 Nebula Species 0.000 description 2
- 241000722336 Pholiota aurivella Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000001785 ferulic acid Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 2
- 229940114124 ferulic acid Drugs 0.000 description 2
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241000222382 Agaricomycotina Species 0.000 description 1
- 244000251953 Agaricus brunnescens Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 241000195952 Equisetaceae Species 0.000 description 1
- 244000085625 Equisetum Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 241000218791 Ginkgoaceae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102100040018 Interferon alpha-2 Human genes 0.000 description 1
- 108010079944 Interferon-alpha2b Proteins 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000722337 Pholiota Species 0.000 description 1
- 241000219050 Polygonaceae Species 0.000 description 1
- 241000205407 Polygonum Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241000218998 Salicaceae Species 0.000 description 1
- 241000534017 Saururus chinensis Species 0.000 description 1
- 241000233932 Sparganium Species 0.000 description 1
- 241001180441 Sparganium stoloniferum Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000233945 Typhaceae Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 241000159213 Zygophyllaceae Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 238000002573 colposcopy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000003050 experimental design method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000007444 viral RNA synthesis Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medical gynecological gel for treating HPV virus infection and a preparation method thereof, wherein the medical gynecological gel comprises the following traditional Chinese medicine compositions in parts by weight: 30-40 parts of pleurotus ostreatus, 20-30 parts of common camptotheca fruit, 10-35 parts of rhizoma sparganii, 10-35 parts of equisetum hiemale, 10-20 parts of elecampane, 7-10 parts of polygonum cuspidatum, 7-10 parts of ginkgo leaf, 7-10 parts of peganum harmala, 5-8 parts of houttuynia cordata and 5-8 parts of oldenlandia diffusa. The formula of the invention is not reported, and the medicine in the formula has exact efficacy, has obvious effect on treating Human Papilloma Virus (HPV) infection, has obvious anti-inflammatory and bacteriostatic effects, and can effectively treat cervicitis, vaginitis and other symptoms caused by HPV.
Description
Technical Field
The invention relates to medical equipment, in particular to a medical gynecological gel for treating HPV virus infection and a preparation method thereof.
Background
Cervical Human Papilloma Virus (HPV) is one of the common diseases in gynecological clinical at present, the incidence rate is in a situation of increasing year by year, and the incidence population is also in a trend of being younger. A large number of epidemiological and molecular biological research data indicate that human papillomavirus HPV is closely related to cervical cancer and precancerous lesions. HPV is a small circular double-stranded DNA virus, is a specific epitheliotropic virus, can cause genital tract infection, and causes serious damage to the health of patients.
At present, effective treatment means for cervical HPV infection is lacked, modern western medicine mainly adopts treatment means such as local physics, immunotherapy, local medication, photodynamic and the like, but has the problems of great toxic and side effects, damage to vaginal mucosa in different degrees, high price, easy recurrence and the like, so the invention provides the medical gynecological gel for treating HPV virus infection. The formula of the invention is not reported, and the medicine in the formula has exact efficacy and has obvious effect of treating HPV virus infection.
The pleurotus ostreatus, also called Pholiota adiposa and Pholiota adiposa, belongs to Hymenomycetes, belongs to Pholiota, grows on trunks of willows and birch in autumn, is a high-quality fungus used as both medicine and food, and the sporocarp or mycelium of the pleurotus ostreatus contains various nutrient components such as protein, cellulose, polysaccharide, amino acid and the like. The main active component of the pleurotus ostreatus is polysaccharide which has biological activities of resisting oxidation, resisting tumors, inhibiting bacteria, regulating immunity and the like.
Camptotheca acuminata fruit is dried mature fruit of Camptotheca acuminata of the family Symplocoaceae. Bitter in taste and cold in nature, it enters spleen, stomach and liver meridians. Has effects of removing blood stasis, relieving swelling and resolving hard mass, and can be used for treating lump under hypochondrium, carbuncle, sore, toxic swelling, and intractable tinea. Modern researches show that the camptotheca acuminate fruit polysaccharide has remarkable activities of inhibiting cancer cell proliferation, inhibiting bacteria, resisting oxidation and the like.
Peganum harmala, a perennial herb of Zygophyllaceae. Has mild nature and bitter and pungent taste, has effects of invigorating tendons and vessels, tonifying yang, warming yin, eliminating viscous body fluid, and eliminating cold-damp, and can be used for treating soft tendons and vessels, unconsciousness, headache, and menoxenia. Modern researches show that alkaloid in peganum harmala can inhibit the activity of DNA topoisomerase, and has antitumor and antibacterial activities.
Rhizoma Sparganii is dried tuber of Sparganium stoloniferum of Sparganiaceae. Has mild nature and bitter taste, has the effects of breaking blood and promoting qi circulation, removing food retention, and dredging channels and relieving pain, and is mainly used for treating diseases such as qi and blood stagnation, chest and abdomen distending pain, amenorrhea and dysmenorrhea. Modern researches show that the Sparganium crispum extract has the activities of improving the hemorheology index, resisting thrombus, resisting tumors, resisting pressure and the like.
Herba Equiseti hiemalis, a dry aerial part of Equisetum hiemalis of Equisetaceae, is sweet and bitter in taste, has neutral nature, has effects of dispelling pathogenic wind and heat, improving eyesight and removing nebula, and is mainly used for treating conjunctival congestion due to wind-heat, epiphora induced by wind, and nebula generated by eyes. Modern pharmacological studies show that the chemical components of the plant extract mainly comprise caffeic acid, ferulic acid, equisetum arvense base and the like, wherein the caffeic acid has wide antibacterial and antiviral effects, and the ferulic acid and the equisetum arvense base can interfere virus RNA synthesis and transplant virus growth.
Inula helenium is dried root of Inula helenium of Compositae, is pungent, bitter, warm in nature, has effects of invigorating spleen and regulating stomach, activating qi-flowing and relieving pain, and preventing miscarriage, and can be used for treating chest distress, abdominal pain, emesis, dysentery, and pain caused by qi stagnation. The study reports that the elecampane inula root has antibacterial, antitumor and anti-inflammatory activities.
Polygonum cuspidatum is dried rhizome and root of perennial shrub-like herbaceous plant of Polygonum of Polygonaceae. Is slightly cold in nature and slightly bitter in taste, and has the effects of promoting bile flow, eliminating jaundice, clearing away heat and toxic materials, removing blood stasis, and relieving pain. Modern pharmacological research shows that giant knotweed has multiple activities of resisting inflammation, resisting bacteria, resisting oxidation, resisting tumor, changing blood rheology and the like.
Folium Ginkgo is dry leaf of Ginkgo biloba L of Ginkgoaceae. Neutral in nature, sweet, bitter and astringent in flavor, and entering heart and lung meridians. Has various pharmacological activities of relieving cough and asthma, regulating blood fat, inhibiting platelet activity, resisting oxidation and tumor, inhibiting bacteria and killing parasites, etc.
Houttuynia cordata, which is a fresh whole plant or dried overground part of houttuynia cordata of the saururus chinensis family, is recorded in famous medical records, is pungent in taste and slightly cold, has the functions of clearing heat and removing toxicity, eliminating carbuncle and expelling pus, and inducing diuresis for treating stranguria, is mainly used for lung carbuncle and empyema, phlegm heat and cough and asthma, and has the activities of resisting inflammation, relieving fever, resisting oxidation and the like as proved by modern researches, and mainly contains volatile oil, alkaloid, flavone, polysaccharide, organic acid and other chemical substances.
Herba Hedyotidis Diffusae is dried whole plant of herba Hedyotidis Diffusae of Rubiaceae. Slightly cold in nature, slightly bitter and sweet in taste. It enters heart, liver and spleen meridians. Has the effects of clearing away heat and toxic materials, eliminating carbuncle, removing furuncle, inducing diuresis, and relieving swelling, and can be used for treating sore throat, lung heat cough and asthma, stranguria with heat, pain, and jaundice due to damp-heat pathogen. Modern pharmacological research shows that the oldenlandia diffusa has various activities of resisting tumor, protecting nerves, diminishing inflammation, resisting oxidation, resisting aging, enhancing immunity and the like.
Disclosure of Invention
The invention provides a medical gynecological gel for treating HPV infection, which solves the problem of poor curative effect of treating human papilloma virus HPV in the existing medicines, and adopts the following technical means:
a medical gynecological gel for treating HPV virus infection comprises the following components in parts by weight: 30-40 parts of pleurotus ostreatus, 20-30 parts of common camptotheca fruit, 10-35 parts of rhizoma sparganii, 10-35 parts of equisetum hiemale, 10-20 parts of elecampane, 7-10 parts of polygonum cuspidatum, 7-10 parts of ginkgo leaf, 7-10 parts of peganum harmala, 5-8 parts of houttuynia cordata and 5-8 parts of oldenlandia diffusa.
Further, the traditional Chinese medicine composition comprises the following components in parts by weight: 34 parts of willow mushroom, 24 parts of common camptotheca fruit, 20 parts of rhizoma sparganii, 20 parts of common scouring rush herb, 14 parts of elecampane, 9 parts of giant knotweed rhizome, 9 parts of ginkgo leaf, 9 parts of peganum harmala, 6 parts of heartleaf houttuynia herb and 6 parts of spreading hedyotis herb.
A medical gynecological gel for treating HPV virus infection is prepared from the traditional Chinese medicine composition.
A medical gynecological gel for the treatment of HPV viral infections comprising the following steps:
(1) taking the traditional Chinese medicine composition in parts by weight, decocting with 8 times and 6 times of distilled water for 2 times, respectively, filtering for 1-2 hours for the first time and 0.5-1.5 hours for the second time, and combining the filtrates;
(2) adding ethanol into the above combined filtrate to make the ethanol content 50-70%, standing at room temperature for 14-24 hr, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.0-1.3;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 5.0-7.0, and stirring to obtain medical gynecological gel for treating HPV virus infection.
Drawings
Fig. 1 is a comparison of a cervical transition zone colposcope of the present invention.
Detailed Description
The invention is further illustrated by the following examples, which are not intended to limit the scope of the invention. The experimental methods used in the following examples are all conventional methods unless otherwise specified; the materials, reagents and the like used are, unless otherwise specified, commercially available reagents and materials.
Example 1
A preparation method of medical gynecological gel for treating HPV virus infection comprises the following steps:
(1) taking 30 parts of willow mushroom, 20 parts of common camptotheca fruit, 10 parts of black common burreed rhizome, 10 parts of common scouring rush herb, 10 parts of elecampane, 7 parts of giant knotweed rhizome, 7 parts of ginkgo leaf, 7 parts of peganum harmala, 5 parts of heartleaf houttuynia herb and 5 parts of spreading hedyotis herb. Decocting with 8 times and 6 times of distilled water for 2 times, 1 hr for the first time and 1.5 hr for the second time, filtering, and mixing filtrates;
(2) adding ethanol into the combined filtrate to make the ethanol content reach 50%, standing at room temperature for 14 hr, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.0;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 5.0, and stirring to obtain medical gynecological gel for treating HPV virus infection.
Example 2
A preparation method of medical gynecological gel for treating HPV virus infection comprises the following steps:
(1) taking 32 parts of agaricus bisporus, 22 parts of common camptotheca fruit, 15 parts of rhizoma sparganii, 15 parts of common scouring rush herb, 12 parts of elecampane, 8 parts of giant knotweed rhizome, 8 parts of ginkgo leaf, 8 parts of peganum harmala, 5 parts of heartleaf houttuynia herb and 5 parts of spreading hedyotis herb. Decocting with 8 times and 6 times of distilled water for 2 times, 1.5 hr for the first time and 1.0 hr for the second time, respectively filtering, and mixing filtrates;
(2) adding ethanol into the combined filtrate to make the ethanol content be 55%, standing at room temperature for 16 hr, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.1;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 5.5, and stirring to obtain medical gynecological gel for treating HPV virus infection.
Example 3
A preparation method of medical gynecological gel for treating HPV virus infection comprises the following steps:
(1) taking 34 parts of willow mushroom, 24 parts of common camptotheca fruit, 20 parts of rhizoma sparganii, 20 parts of common scouring rush herb, 14 parts of elecampane, 9 parts of giant knotweed rhizome, 9 parts of ginkgo leaf, 9 parts of peganum harmala, 6 parts of heartleaf houttuynia herb and 6 parts of spreading hedyotis herb. Decocting with 8 times and 6 times of distilled water for 2 times, 2 hr for the first time and 0.5 hr for the second time, respectively filtering, and mixing filtrates;
(2) adding ethanol into the combined filtrate to make the ethanol content reach 60%, standing at room temperature for 18 hr, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.2;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 6.0, and stirring to obtain medical gynecological gel for treating HPV virus infection.
Example 4
A preparation method of medical gynecological gel for treating HPV virus infection comprises the following steps:
(1) taking 36 parts of willow mushroom, 26 parts of common camptotheca fruit, 25 parts of black common burreed rhizome, 25 parts of common scouring rush herb, 16 parts of elecampane, 10 parts of giant knotweed rhizome, 9 parts of ginkgo leaf, 9 parts of peganum harmala, 7 parts of heartleaf houttuynia herb and 7 parts of spreading hedyotis herb. Decocting with 8 times and 6 times of distilled water for 2 times, 2 hr for the first time and 1 hr for the second time, respectively filtering, and mixing filtrates;
(2) adding ethanol into the combined filtrate to make the ethanol content 65%, standing at room temperature for 20 hr, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.3;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 6.5, and stirring to obtain medical gynecological gel for treating HPV virus infection.
Example 5
A preparation method of medical gynecological gel for treating HPV virus infection comprises the following steps:
(1) taking 38 parts of willow mushroom, 28 parts of common camptotheca fruit, 30 parts of black common burreed rhizome, 30 parts of common scouring rush herb, 18 parts of elecampane, 9 parts of giant knotweed rhizome, 8 parts of ginkgo leaf, 7 parts of peganum harmala, 8 parts of heartleaf houttuynia herb and 8 parts of spreading hedyotis herb. Decocting with 8 times and 6 times of distilled water for 2 times, 1.5 hr for the first time and 1.5 hr for the second time, respectively filtering, and mixing filtrates;
(2) adding ethanol into the combined filtrate to make the ethanol content of the filtrate 70%, standing at room temperature for 22 hours, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.0;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 7.0, and stirring to obtain medical gynecological gel for treating HPV virus infection.
Example 6
A preparation method of medical gynecological gel for treating HPV virus infection comprises the following steps:
(1) taking 40 parts of willow mushroom, 30 parts of common camptotheca fruit, 35 parts of black common burreed rhizome, 35 parts of common scouring rush herb, 20 parts of elecampane, 10 parts of giant knotweed rhizome, 10 parts of ginkgo leaf, 10 parts of peganum harmala, 8 parts of heartleaf houttuynia herb and 8 parts of spreading hedyotis herb. Decocting with 8 times and 6 times of distilled water for 2 times, 2 hr for the first time and 1.5 hr for the second time, respectively filtering, and mixing filtrates;
(2) adding ethanol into the combined filtrate to make the ethanol content of the filtrate 70%, standing at room temperature for 24 hours, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.3;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 7.0, and stirring to obtain medical gynecological gel for treating HPV virus infection.
To verify that the medical gynecological gel prepared by the method of example 3 has efficacy of treating HPV viral infection, the following clinical experiments were performed:
1. experimental materials and methods
1.1 general data
80 cases of HPV infected patients are selected, and are divided into 40 cases of an experimental group and 40 cases of a control group according to the ratio of 1:1 by adopting an open random control experimental design method.
And (3) inclusion standard: (1) female aged from l 8-50 years; (2) positive for vaginal secretion HPV virus detection; (3) volunteer to participate in clinical trials and sign informed consent. Exclusion criteria: (1) patients in gestation and lactation periods are excluded; (2) patients who failed to fit were excluded.
1.2 Experimental methods
Patients in experimental groups were administered with a medical gynecological gel against HPV infection before sleep, and the gel applicator was gently inserted into the deep vagina and pushed into the gel 1 time a day, 1 tube at a time. The recombinant human interferon alpha 2b suppository is given to the patients in the control group before sleeping 1 time a day and 1 tablet each time. The treatment course of the two groups of patients is 30 days.
2. Results of the experiment
2.1 Total improvement in efficacy of two groups of patients after 30 days of treatment
The judgment standard of the curative effect is as follows: (1) and (3) healing: the integral ratio of clinical symptoms and physical signs is more than or equal to 90 percent; (2) the effect is shown: clinical symptoms are more than or equal to 60 percent, and the integral rate of physical signs is less than 90 percent; (3) the method has the following advantages: clinical symptoms are more than or equal to 30 percent, and the integral rate of physical signs is less than 60 percent; (4) ineffective clinical symptoms, signs integration < 30%. Integrated ratio ═ (total before treatment-total after treatment)/total before treatment x 100%. Total good conversion rate is recovery rate + significant efficiency + effective rate.
The total improvement rate of the experimental group is 82.5 percent, the total improvement rate of the control group is 62.5 percent, and the two groups of treatment have significant difference (P is less than 0.05), which indicates that the curative effect of the experimental group is better than that of the control group. The results are shown in Table 1.
Table 1 the combined effect total effective rate (n ═ 40) after 30 days of treatment for two groups of patients
2.2 comparison of HPV viral load before and after treatment in two groups of patients
After 30 days of treatment, the HPV viral load of the experimental group is reduced to 12.86 +/-2.32 pg/mL, the HPV viral load of the control group is reduced to 27.32 +/-2.98 pg/mL, and the two groups have significant differences (P <0.05) in comparison of treatment effects, which shows that the reduction effect of the HPV viral load of the experimental group is obviously better than that of the control group. The results are shown in Table 2.
TABLE 2 comparison of HPV viral load before and after treatment of two groups of patients
Note: comparing with control group*p<0.05。
2.3 comparison of the negative conversion rates of HPV viruses after treatment in two groups of patients
After 30 days of treatment, the negative conversion rate of HPV in the experimental group (87.5%) is higher than that in the control group (72.5%). Significant difference (P <0.05) exists in the comparison of the two groups of treatment, which shows that the curative effect of the experimental group is better than that of the control group. The results are shown in Table 3.
TABLE 3 comparison of HPV negative conversion rates after treatment of two groups of patients
2.4 cervical transition zone colposcopy comparison after 30 days of treatment
After 30 days of treatment of the two groups of patients, it can be observed that the treatment effect of cervical HPV infection by the experimental group is obviously better than that of the control group, and the result is shown in figure 1.
3. Conclusion of the experiment
The above results show that after 30 days of treatment, the total good conversion rate, the virus load reduction and the negative conversion rate of the HPV curative effect of the experimental group are all superior to those of the control group, so that the medical gynecological gel for treating HPV infection can effectively treat HPV infection and has clinical application value.
The above description is only a preferred embodiment of the present invention, and the protection scope of the present invention is not limited to the above embodiments, and all technical solutions belonging to the idea of the present invention belong to the protection scope of the present invention. Several modifications and adaptations of the present invention without departing from its principles should be considered within the scope of the present invention.
Claims (5)
1. A medical gynecological gel for treating HPV virus infection comprises the following components in parts by weight: 30-40 parts of pleurotus ostreatus, 20-30 parts of common camptotheca fruit, 10-35 parts of rhizoma sparganii, 10-35 parts of equisetum hiemale, 10-20 parts of elecampane, 7-10 parts of polygonum cuspidatum, 7-10 parts of ginkgo leaf, 7-10 parts of peganum harmala, 5-8 parts of houttuynia cordata and 5-8 parts of oldenlandia diffusa.
2. The traditional Chinese medicine composition according to claim 1, which is characterized by comprising the following components in parts by weight: 34 parts of willow mushroom, 24 parts of common camptotheca fruit, 20 parts of rhizoma sparganii, 20 parts of common scouring rush herb, 14 parts of elecampane, 9 parts of giant knotweed rhizome, 9 parts of ginkgo leaf, 9 parts of peganum harmala, 6 parts of heartleaf houttuynia herb and 6 parts of spreading hedyotis herb.
3. A medical gynecological gel for treating HPV infection and a preparation method thereof, which is prepared from the traditional Chinese medicine composition of any one of claims 1 to 2.
4. A medical gynecological gel for treating HPV infection and a preparation method thereof are characterized by comprising the following steps:
(1) taking the traditional Chinese medicine composition according to any one of claims 1 to 2, decocting with 8 times and 6 times of distilled water for 2 times, 1-2 hours for the first time and 0.5-1.5 hours for the second time respectively, filtering respectively, and combining the filtrates;
(2) adding ethanol into the above combined filtrate to make the ethanol content 50-70%, standing at room temperature for 14-24 hr, filtering, recovering ethanol, and concentrating to obtain paste with relative density of 1.0-1.3;
(3) adding gel excipient carbomer, humectant glycerol and adhesive cellulose derivative into the paste, adding triethanolamine, adjusting pH to 5.0-7.0, and stirring to obtain medical gynecological gel for treating HPV virus infection.
5. A medical gynecological gel for treating HPV infection and a preparation method thereof are characterized in that the gynecological gel is suitable for symptoms of congestion, edema, secretion increase, pruritus, pustule under the belt and the like caused by cervicitis caused by HPV, and the erosion area of the gynecological gel can be reduced. And is also suitable for symptoms of increased secretion, pruritus, pain, fishy smell and the like caused by vaginitis caused by HPV virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210184541.9A CN114470123A (en) | 2022-02-28 | 2022-02-28 | Medical gynecological gel for treating HPV (human papillomavirus) infection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210184541.9A CN114470123A (en) | 2022-02-28 | 2022-02-28 | Medical gynecological gel for treating HPV (human papillomavirus) infection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114470123A true CN114470123A (en) | 2022-05-13 |
Family
ID=81485225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210184541.9A Withdrawn CN114470123A (en) | 2022-02-28 | 2022-02-28 | Medical gynecological gel for treating HPV (human papillomavirus) infection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114470123A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908559A (en) * | 2012-09-26 | 2013-02-06 | 韩临晓 | External-use Chinese herbal medicine preparation for curing human papilloma virus infection |
| CN106421673A (en) * | 2016-12-13 | 2017-02-22 | 上海世道健康科技有限公司 | Traditional Chinese medicine composition for treating HPV (human papillomavirus) infection and preparation method thereof |
| CN108853287A (en) * | 2018-08-07 | 2018-11-23 | 吉林省正肽生物科技有限公司 | Pharmaceutical composition, gel preparation and the application of a kind of anti-human papilloma virus (anti-HPV) and anti-gynaecological imflammation |
| CN111588780A (en) * | 2020-07-09 | 2020-08-28 | 广西妙韵圆生药业有限公司 | Traditional Chinese medicine composition for treating cervical HPV (human papillomavirus) infection and preparation method thereof |
-
2022
- 2022-02-28 CN CN202210184541.9A patent/CN114470123A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102908559A (en) * | 2012-09-26 | 2013-02-06 | 韩临晓 | External-use Chinese herbal medicine preparation for curing human papilloma virus infection |
| CN106421673A (en) * | 2016-12-13 | 2017-02-22 | 上海世道健康科技有限公司 | Traditional Chinese medicine composition for treating HPV (human papillomavirus) infection and preparation method thereof |
| CN108853287A (en) * | 2018-08-07 | 2018-11-23 | 吉林省正肽生物科技有限公司 | Pharmaceutical composition, gel preparation and the application of a kind of anti-human papilloma virus (anti-HPV) and anti-gynaecological imflammation |
| CN111588780A (en) * | 2020-07-09 | 2020-08-28 | 广西妙韵圆生药业有限公司 | Traditional Chinese medicine composition for treating cervical HPV (human papillomavirus) infection and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108853287B (en) | Pharmaceutical composition for resisting human papilloma virus and gynecological inflammation, gel preparation and application | |
| CN103893722A (en) | Traditional Chinese medicinal composition for treating solar dermatitis and preparation method thereof | |
| CN112569332A (en) | Application of bupleurum tenue extract in treating viral pneumonia | |
| CN103768398A (en) | Traditional Chinese medicine composition for treating advanced lung tumors | |
| CN104887617A (en) | Composition for nursing eyes and preparation method of composition | |
| EP3821902B1 (en) | Traditional chinese medicine composition, traditional chinese medicine compound preparation and preparation method and use thereof | |
| CN103877287A (en) | Medicine for treating breast cancer and preparation method thereof | |
| CN114917298B (en) | Pharmaceutical composition for treating pneumonia and preparation method thereof | |
| CN104173592A (en) | Isodon amethystoides herbal tea drink and preparation method thereof | |
| CN114470123A (en) | Medical gynecological gel for treating HPV (human papillomavirus) infection and preparation method thereof | |
| CN102327204B (en) | Oral care preparation and production method thereof | |
| CN113616721A (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
| CN108420936A (en) | A kind of traditional Chinese powder medicine for treating canker sore | |
| CN102755519B (en) | Kudzuvine root-kudzuvine flower anti-canker sore particle and preparation method thereof | |
| CN113332357A (en) | Composition and preparation for improving cervical HPV infection symptoms and preparation method | |
| CN106109626A (en) | A kind of pharmaceutical composition with antitumor action and its production and use | |
| CN104645082A (en) | Capsule for treating hepatitis and preparation method thereof | |
| CN102716421A (en) | Chinese medicine oral liquid for treating flat wart and preparation method of Chinese medicine oral liquid | |
| CN104225338A (en) | Medicine for treating viral pneumonia and preparation method thereof | |
| CN104524124A (en) | Traditional Chinese medicinal preparation for treating skull osteomyelitis and preparation method | |
| CN1085439A (en) | A kind of anticancer herbal drug | |
| CN108704040B (en) | Traditional Chinese medicine composition and application thereof | |
| CN108524797A (en) | A kind of preparation method and applications for treating swine fever bacterium solution | |
| CN114470139B (en) | Traditional Chinese medicine composition for treating liver cancer and preparation method thereof | |
| CN109820826B (en) | Anti-inflammatory traditional Chinese medicine granules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220513 |